COVID-19 vaccine-associated myocarditis (C-VAM) has a mild initial clinical course, but myocardial injury is common, according to a study published online in the October issue of eClinicalMedicine . Supriya S. Jain, M.
D., from New York Medical College-Maria Fareri Children's Hospital at Westchester Medical Center in Valhalla, and colleagues examined the clinical characteristics, myocardial injury , and longitudinal outcomes of C-VAM. A total of 333 patients aged 30 years or younger with C-VAM were compared to 100 patients with multisystem inflammatory syndrome in children (MIS-C).
The presence of myocardial injury as evidenced by late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) imaging was the primary outcome. Patients with C-VAM were mainly White (67%), adolescent (age, 15.7 ±2.
8 years) males (91%). The researchers found that compared with MIS-C, the initial clinical course of C-VAM was significantly more likely to be mild (80 versus 23%) and cardiac dysfunction was less common (17 versus 68%). LGE on CMR was significantly more prevalent in C-VAM than MIS-C (82 versus 16%).
The probability of LGE was significantly higher in male and older patients and when C-VAM occurred after the first or second versus the third mRNA vaccine dose. At a median follow-up of 178 days, midterm clinical outcomes of C-VAM were reassuring. In 60% of patients, LGE persisted at follow-up.
"While midterm clinical sequelae are rare and LGE severity decreases over time, the persistence of LGE at follow-up in most patients warrants continued clinical surveillance, additional research, and longer-term studies in this subset of patients," the authors write. Several authors disclosed ties to relevant organizations. More information: Supriya S.
Jain et al, Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study, eClinicalMedicine (2024). DOI: 10.1016/j.
eclinm.2024.102809 © 2024 HealthDay .
All rights reserved..
